Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities (Q40822804)

24 September 2017

Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities (English)

1 reference

24 September 2017

16

1 reference

24 September 2017

Volker Hovestadt

7

0 references

Stefan M. Pfister

Stefan M Pfister

21

0 references

Michael Weller

23

Michael Weller

1 reference

24 September 2017

25

Wolfgang Wick

1 reference

PubMed ID

26087904

24 September 2017

Melanie Bewerunge-Hudler

8

Melanie Bewerunge-Hudler

1 reference

24 September 2017

3

Felix Sahm

1 reference

24 September 2017

27

Andreas von Deimling

1 reference

24 September 2017

18

Guido Reifenberger

1 reference

24 September 2017

4

David Capper

1 reference

PubMed ID

26087904

24 September 2017

Christel Herold-Mende

24

Christel Herold-Mende

1 reference

24 September 2017

10

Jens Schittenhelm

1 reference

24 September 2017

5

Daniel Schrimpf

1 reference

24 September 2017

11

Michel Mittelbronn

1 reference

24 September 2017

22

Andrey Korshunov

1 reference

24 September 2017

9

David T W Jones

1 reference

24 September 2017

1

David E Reuss

1 reference

24 September 2017

20

Kenneth Aldape

1 reference

24 September 2017

12

Elisabeth Rushing

1 reference

24 September 2017

2

Annekathrin Kratz

1 reference

24 September 2017

6

Christian Koelsche

1 reference

24 September 2017

13

Matthias Simon

1 reference

24 September 2017

14

Manfred Westphal

1 reference

24 September 2017

17

Werner Paulus

1 reference

24 September 2017

26

Sebastian Brandner

1 reference

24 September 2017

19

Joerg-Christian Tonn

1 reference

24 September 2017

Andreas Unterberg

15

1 reference

24 September 2017

19 June 2015

1 reference

24 September 2017

Acta Neuropathologica

1 reference

24 September 2017

130

1 reference

24 September 2017

407-417

1 reference

24 September 2017

3

1 reference

https://scigraph.springernature.com/pub.10.1007/s00401-015-1454-8

24 September 2017

0 references

cites work

Analysis of the IDH1 codon 132 mutation in brain tumors

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1454-8

Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1454-8

Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1454-8

Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1454-8

Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1454-8

What do we know about IDH1/2 mutations so far, and how do we use it?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1454-8

IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1454-8

TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1454-8

Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1454-8

Mutant BRAF V600E protein in ganglioglioma is predominantly expressed by neuronal tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1454-8

All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1454-8

International Society Of Neuropathology--Haarlem consensus guidelines for nervous system tumor classification and grading

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1454-8

Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1454-8

IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1454-8

An integrated genomic analysis of human glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1454-8

Landscape of chromosomal copy number aberrations in gangliogliomas and dysembryoplastic neuroepithelial tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1454-8

IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1454-8

ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1454-8

Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1454-8

Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1454-8

Mutational landscape and clonal architecture in grade II and III gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1454-8

IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1454-8

A sensitive and specific histopathologic prognostic marker for H3F3A K27M mutant pediatric glioblastomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1454-8

Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1454-8

Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1454-8

IDH1 and IDH2 mutations in gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1454-8

Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1454-8

10.1007/S00401-015-1454-8

21 January 2018

Identifiers

DOI

1 reference

24 September 2017

1 reference

PubMed ID

26087904